Wegener's disease (now called Granulomatosis with polyangiitis) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Granulomatosis with polyangiitis (GPA), historically known as Wegener’s granulomatosis, is a rare, systemic autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels. The inflammation can lead to necrotizing granulomas (tiny clusters of immune cells) mainly in the respiratory tract and kidneys, but any organ can be involved.

• Prevalence: Approximately 3 – 4 cases per 100,000 adults worldwide (CDC, 2022).
• Typical age of onset: 40–60 years, though children and adolescents can be affected.
• Gender distribution: Slight male predominance (about 1.3 : 1), but the disease occurs in both sexes.
• Geography: No strong ethnic or regional pattern; it is reported globally.

Because GPA can involve lungs, ears, nose, sinuses, kidneys, skin, eyes, and nerves, its presentation is often variable, which can delay diagnosis. Early recognition and treatment dramatically improve outcomes: the 5‑year survival rate has risen from < 30 % before modern therapy to > 80 % with current treatment regimens (NIH, 2023).

Symptoms

Symptoms reflect the organs that are inflamed. They may appear suddenly or develop gradually over months.

Upper respiratory tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or post‑nasal drip.
• Nasal ulceration or crusting – often painless, may bleed.
• Ear problems – hearing loss, otitis media, or ear pain.
• Sore throat – can be severe and refractory to typical antibiotics.

Lower respiratory tract

• Cough – dry or productive.
• Hemoptysis – coughing up blood (often a red flag).
• Shortness of breath – due to lung nodules, infiltrates, or alveolar hemorrhage.
• Chest pain – pleuritic in nature.

Renal involvement

• Hematuria – visible (gross) or microscopic blood in urine.
• Proteinuria – foamy urine indicating protein loss.
• Reduced kidney function – fatigue, swelling (edema) of ankles, or hypertension.

Systemic / General

• Fever, night sweats, unexplained weight loss.
• Fatigue, malaise.
• Arthralgia (joint pain) without swelling.
• Peripheral neuropathy – tingling or weakness, especially in the hands/feet.

Other organ systems

• Eyes: Redness, blurry vision, scleritis.
• Skin: Purpura, nodules, or ulcerated lesions.
• Cardiovascular: Rarely, myocarditis or pericarditis.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility, environmental exposure, and an aberrant immune response.

Immunologic factors

• ANCA antibodies – > 90 % of patients have anti‑proteinase‑3 (PR3‑ANCA) antibodies, which are thought to activate neutrophils and damage vessel walls.

Genetic predisposition

• Certain HLA‑DPB1 and HLA‑DQ alleles are modestly associated with higher risk (Cleveland Clinic, 2023).

Environmental exposures

• Silica dust, farming chemicals, and chronic nasal carriage of Staphylococcus aureus have been linked to increased incidence, though causality is still under investigation.

Demographic risk factors

• Age 40‑60, male sex, and northern European ancestry show slightly higher rates.
• Smoking may exacerbate lung involvement but is not a proven cause.

Diagnosis

Because GPA mimics infections, malignancies, and other vasculitides, a systematic approach is essential.

Clinical assessment

• Detailed history of organ‑specific symptoms.
• Physical examination focusing on ENT, pulmonary, renal, and skin findings.

Laboratory tests

• ANCA testing – Indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA and MPO‑ANCA. Positive PR3‑ANCA is highly suggestive of GPA.
• Complete blood count (CBC) – often shows anemia or leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria and proteinuria.
• Inflammatory markers – ESR & CRP are usually elevated.

Imaging studies

• Chest X‑ray or CT scan – detects nodules, cavitations, infiltrates, or alveolar hemorrhage.
• Sinus CT – evaluates chronic sinusitis, bone destruction, or ulceration.

Biopsy (definitive diagnosis)

• Histopathology showing necrotizing granulomatous inflammation with vasculitis is the gold standard.
• Common sites: nasal mucosa, lung tissue (trans‑bronchial), or kidney (renal biopsy) when renal disease is present.

Diagnostic criteria

The 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria use a point‑system (clinical, serologic, and pathological features). A score ≥ 5 classifies a patient as having GPA (ACR/EULAR, 2022).

Treatment Options

Therapy aims to induce remission quickly, then maintain disease control while minimizing drug toxicity.

Induction therapy (to achieve remission)

• Corticosteroids – high‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500‑1000 mg/day for 3 days) for severe organ involvement.
• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks (or 1 g on days 1 & 15). Equivalent efficacy to cyclophosphamide, with fewer long‑term toxicities (NEJM, 2015).
• Cyclophosphamide – oral (2 mg/kg/day) or IV (15 mg/kg every 2‑3 weeks) for 3‑6 months in life‑threatening disease when rituximab is unavailable.
• Plasma exchange (PLEX) – considered for rapidly progressive glomerulonephritis or diffuse alveolar hemorrhage (Guidelines, KDIGO 2023).

Maintenance therapy (to prevent relapse)

• Azathioprine 2‑2.5 mg/kg/day.
• Mycophenolate mofetil 1‑1.5 g twice daily (alternative for patients intolerant of azathioprine).
• Rituximab – 500 mg IV every 6 months for up to 2 years based on relapse risk.
• Low‑dose prednisone (≤ 5 mg/day) is often continued for the first 12–18 months.

Adjunctive measures

• Prophylaxis for opportunistic infections: Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1 tablet three times weekly reduces risk of Pneumocystis jirovecii pneumonia and may lower GPA relapse.
• Vaccinations – influenza, pneumococcal, COVID‑19, and hepatitis B before initiating immunosuppression.
• Bone health – calcium, vitamin D, and bisphosphonates if on long‑term steroids.

Lifestyle and supportive care

• Smoking cessation to protect lung health.
• Regular exercise as tolerated to maintain muscle strength.
• Psychological support – chronic disease can cause anxiety/depression; referral to counseling may help.

Living with Granulomatosis with Polyangiitis

Even after remission, ongoing self‑management is crucial.

Medication adherence

• Set reminders (phone alarms, pill boxes).
• Keep a medication list and share it with every health‑care provider.

Monitoring

• Blood tests every 1‑3 months initially (CBC, renal function, ANCA titers); frequency can be spaced out once stable.
• Urinalysis at each visit to catch early kidney involvement.
• Annual chest X‑ray or low‑dose CT if lung disease was present.

Managing flare‑ups

• Track symptoms in a diary – note new sinus pain, hematuria, cough, or fever.
• Contact your rheumatology/urology team early; prompt escalation of steroids often prevents organ damage.

Daily living tips

• Stay hydrated – helps kidney function.
• Practice nasal saline irrigation to reduce crusting and infection risk.
• Use protective masks in dusty environments.
• Maintain a balanced diet rich in fruits, vegetables, lean protein, and whole grains.
• Limit alcohol, especially when on hepatotoxic drugs (e.g., azathioprine).

Emotional wellbeing

• Join support groups (e.g., Vasculitis Foundation). Sharing experiences reduces isolation.
• Consider mindfulness or gentle yoga to manage stress, which can influence immune activity.

Prevention

Because GPA’s root cause is not fully understood, primary prevention is limited. However, risk reduction strategies include:

• Avoiding prolonged silica exposure (protective respirators in construction, mining, sandblasting).
• Prompt treatment of chronic sinus infections and eradication of S. aureus carriage when indicated.
• Smoking cessation to protect airway integrity.
• Regular health check‑ups in individuals with a family history of autoimmune disease.

Complications

If left untreated or inadequately controlled, GPA can cause irreversible organ damage.

• Renal failure – crescentic glomerulonephritis may progress to end‑stage kidney disease requiring dialysis or transplantation.
• Permanent lung injury – fibrosis, cavitary lesions, or bronchiectasis leading to chronic respiratory insufficiency.
• Hearing loss or facial nerve palsy from chronic middle ear disease.
• Vision loss – scleritis or orbital granulomas can threaten sight.
• Peripheral neuropathy – may become chronic and disabling.
• Infections – immunosuppressive therapy heightens risk of bacterial, viral, and fungal infections.
• Thromboembolic events – vasculitis‑related endothelial injury can precipitate clots.

When to Seek Emergency Care

References

• Mayo Clinic. Granulomatosis with Polyangiitis (Wegener’s). https://www.mayoclinic.org/diseases‑conditions/granulomatosis‑with‑polyangiitis‑wegener’s‑symptoms‑causes/symptoms‑causes/rc‑20353943 (accessed May 2026).
• Centers for Disease Control and Prevention (CDC). “Vasculitis Statistics.” 2022.
• National Institutes of Health (NIH). “Granulomatosis with Polyangiitis: Treatment Guidelines.” 2023.
• Cleveland Clinic. “ANCA‑Associated Vasculitis.” 2023.
• Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Vasculitis. 2023.
• American College of Rheumatology / EULAR. “2022 Classification Criteria for Granulomatosis with Polyangiitis.” Arthritis Rheumatol. 2022.
• Jayne D.R., et al. “Rituximab versus Cyclophosphamide for ANCA‑Associated Vasculitis.” New England Journal of Medicine. 2015;373(19): 1906‑1915.
• World Health Organization (WHO). “Vaccination Recommendations for Immunocompromised Adults.” 2024.

```